The most recent 2021 classification from the World Health Organization (WHO) divides these tumors into astrocytomas, oligodendrogliomas, and glioblastomas (GBMs) based on histologic features and the presence or absence of a somatic mutation in the IDH1/2 genes [1]. This evidence concerns the gene IDH1 and oligodendroglioma.